Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ContraFect Co. stock logo
CFRX
ContraFect
$0.05
$0.05
$0.04
$13.02
$535K0.291.39 million shs910,216 shs
Equillium, Inc. stock logo
EQ
Equillium
$0.36
+3.1%
$0.36
$0.27
$1.50
$12.82M1.86464,592 shs230,320 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.33
-7.7%
$0.36
$0.22
$4.79
$13.59M-0.281.09 million shs286,501 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.15
+1.4%
$2.19
$1.82
$3.09
$87.83M1.59141,093 shs14,249 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.43
-0.9%
$0.36
$0.22
$3.64
$17.70M-0.413.13 million shs310,786 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ContraFect Co. stock logo
CFRX
ContraFect
0.00%0.00%0.00%0.00%0.00%
Equillium, Inc. stock logo
EQ
Equillium
+3.29%+6.48%-0.68%-27.31%-52.43%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
+4.26%+23.33%-14.96%+9.63%-81.88%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-2.30%-2.93%-4.93%+0.47%-14.86%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+1.34%+5.86%+22.84%+39.32%-87.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
1.8721 of 5 stars
3.22.00.00.01.11.70.6
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.5975 of 5 stars
3.02.00.00.01.10.01.3
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.2984 of 5 stars
0.03.00.00.00.00.80.6
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.4938 of 5 stars
0.05.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ContraFect Co. stock logo
CFRX
ContraFect
0.00
N/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00749.86% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.38875.43% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/A($19.92) per shareN/A
Equillium, Inc. stock logo
EQ
Equillium
$41.10M0.31N/AN/A$0.54 per share0.65
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M65.39N/AN/A$3.61 per share0.59
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.85M3.05N/AN/A$0.25 per share1.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ContraFect Co. stock logo
CFRX
ContraFect
-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/A
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)

Latest EQ, CFRX, PRPH, LPTX, and ORMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q1 2025
Equillium, Inc. stock logo
EQ
Equillium
-$0.1850N/AN/AN/AN/AN/A
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ContraFect Co. stock logo
CFRX
ContraFect
N/A
0.53
0.53
Equillium, Inc. stock logo
EQ
Equillium
N/A
2.70
2.70
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98

Institutional Ownership

CompanyInstitutional Ownership
ContraFect Co. stock logo
CFRX
ContraFect
7.85%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
ContraFect Co. stock logo
CFRX
ContraFect
0.62%
Equillium, Inc. stock logo
EQ
Equillium
31.60%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
13.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ContraFect Co. stock logo
CFRX
ContraFect
2310.70 million10.64 millionNot Optionable
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.43 millionNot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable

Recent News About These Companies

ProPhase Labs Q1 2025 Earnings Preview
ProPhase Labs's Earnings Outlook
ProPhase Labs Delays Form 10-Q Filing
ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ContraFect stock logo

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Equillium stock logo

Equillium NASDAQ:EQ

$0.36 +0.01 (+3.10%)
As of 03:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.33 -0.03 (-7.66%)
As of 03:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.15 +0.03 (+1.42%)
As of 03:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.43 0.00 (-0.88%)
As of 03:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.